31 October 2025
31 October 2025
In this issue, the evolution of cleanroom design, the rise of green manufacturing, highlights from SCOPE 2025, and more
While Pfizer called the bid 鈥渞eckless鈥�, Metsera disagrees, stating that it will review the 鈥渟uperior proposal鈥�.
Mounjaro and Zepbound sales fuelled Eli Lilly鈥檚 strong Q3, which surpassed analyst forecasts.
The draft guidance, which is touted as a way to reduce the cost and time-associated burden of biosimilar development, has been met with mixed industry reaction.
The decision by the Canadian regulator is supported by the findings from the Phase III DESTINY-Breast06 study.
NetTargets employs an AI system that combines multi-omics data with neural network modelling for drug discovery.
The company is developing programmable non-viral LNP therapies to deliver therapeutic cargo to kidney cells.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
